The subsequent EMPOWER‐Lung 3 trial assessed cemiplimab in combination with platinum‐doublet chemotherapy, administered regardless of PD‐L1 expression, in both squamous and nonsquamous NSCLC [61]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.